Clinical Research

Zipraisidone effectiveness study: A three-phase study designed to test the efficacy, tolerability and safety of the combination of Ziprasidone with the selective serotonin reuptake inhibitor (SSRI) Escitalopram for patients with Major Depressive Disorder (MDD) that do not sufficiently respond to treatment with Escitalopram

The current research study is looking for participants between the ages of 18-65, who are depressed. If eligible, participants will receive the FDA approved antidepressant medication Escitalopram (Lexapro) for at least 8 weeks. At the end of 8 weeks, subjects who have improved on the medication will be offered 3 months of follow up care at no cost.

For those subjects who have NOT improved on the medication, they may be eligible to continue on Lexapro and receive, in addition, either Ziprasidone or placebo. Placebo is sometimes called a sugar pill, and it looks like a study drug but does not contain any active medication. Participants would be assigned to receive Ziprasidone or placebo by chance, like the flip of a coin. At the end of the study, all participants will be offered 3 months of follow up care at no cost.

For more information about this and other depression studies, please call 1-877-55- BLUES or contact Clair directly at 617-724-3673 or ccassiello@partners.org. We initiate new studies regularly, so please contact us for additional information.